Metrics to compare | VNRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVNRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −39.8x | −0.5x | |
PEG Ratio | −0.02 | 0.00 | 0.00 | |
Price/Book | −0.4x | 0.6x | 2.6x | |
Price / LTM Sales | 5.1x | 9.0x | 3.0x | |
Upside (Analyst Target) | - | 13.9% | 58.6% | |
Fair Value Upside | Unlock | −23.9% | 10.2% | Unlock |
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.